[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Protagonist Therapeutics Inc (PTGX)

Protagonist Therapeutics Inc (PTGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,181,156
  • Shares Outstanding, K 64,708
  • Annual Sales, $ 46,020 K
  • Annual Income, $ -130,150 K
  • EBIT $ 58 M
  • EBITDA $ 54 M
  • 60-Month Beta 1.78
  • Price/Sales 223.05
  • Price/Cash Flow N/A
  • Price/Book 12.12

Options Overview Details

View History
  • Implied Volatility 45.11% (+1.30%)
  • Historical Volatility 44.39%
  • IV Percentile 27%
  • IV Rank 28.37%
  • IV High 69.06% on 07/13/26
  • IV Low 35.62% on 11/17/25
  • Expected Move (DTE 2) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 62
  • Volume Avg (30-Day) 170
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 7,777
  • Open Int (30-Day) 7,519
  • Expected Range 154.94 to 154.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $2.19
  • Number of Estimates 4
  • High Estimate $3.27
  • Low Estimate $0.65
  • Prior Year $-0.62
  • Growth Rate Est. (year over year) +453.23%

Price Performance

See More
Period Period Low Period High Performance
1-Month
130.63 +18.61%
on 07/30/26
160.81 -3.65%
on 08/19/26
+14.03 (+9.96%)
since 07/17/26
3-Month
92.75 +67.05%
on 06/02/26
160.81 -3.65%
on 08/19/26
+56.57 (+57.51%)
since 05/19/26
52-Week
54.50 +184.29%
on 09/09/25
160.81 -3.65%
on 08/19/26
+98.69 (+175.45%)
since 08/19/25

Most Recent Stories

More News
Protagonist Therapeutics Reports Granting of Inducement Awards

NEWARK, CA / ACCESS Newswire / August 18, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on August 17, 2026, it granted inducement awards to two recently hired employees in accordance...

PTGX : 154.94 (-1.53%)
Protagonist Therapeutics: Q2 Earnings Snapshot

Protagonist Therapeutics: Q2 Earnings Snapshot

PTGX : 154.94 (-1.53%)
Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update

ICOTYDE™ First Full Quarter of Commercial Sales with Strong Early Adoption

PTGX : 154.94 (-1.53%)
Protagonist Therapeutics: When Pipeline Promise Meets Revenue Reality Check

Barchart Research What to Expect from PTGX Earnings PTGX Generated August 4, 2026 Current Price $135.81 EPS Estimate $$2.11 Consensus Rating Strong Buy Average Move 3.21% Protagonist Therapeutics: When...

PTGX : 154.94 (-1.53%)
Protagonist Therapeutics Reports Granting of Inducement Awards

NEWARK, CA / ACCESS Newswire / August 4, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on July 31, 2026, it granted inducement awards to two recently hired employees in accordance...

PTGX : 154.94 (-1.53%)
Protagonist Therapeutics Reports Granting of Inducement Awards

NEWARK, CA / ACCESS Newswire / July 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on July 15, 2026, it granted inducement awards to three recently hired employees in accordance...

PTGX : 154.94 (-1.53%)
Why Wall Street’s Wrong for Loving Protagonist Therapeutics Stock

Protagonist Therapeutics (PTGX) exhibits strong technical momentum, posting a 150% gain over the past 52 weeks. PTGX holds a 100% “Buy” technical opinion from Barchart. Despite bullish analyst sentiment...

PTGX : 154.94 (-1.53%)
Protagonist Therapeutics Reports Granting of Inducement Awards

NEWARK, CA / ACCESS Newswire / July 1, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on June 30, 2026, it granted inducement awards to three recently hired employees in accordance...

PTGX : 154.94 (-1.53%)
Protagonist Therapeutics Reports Granting of Inducement Awards

NEWARK, CA / ACCESS Newswire / June 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on June 15, 2026, it granted inducement awards to three recently hired employees in accordance...

PTGX : 154.94 (-1.53%)
Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress

NEWARK, CA / ACCESS Newswire / June 1, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that four abstracts highlighting rusfertide in polycythemia vera (PV) will...

PTGX : 154.94 (-1.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and...

See More

Key Turning Points

3rd Resistance Point 165.68
2nd Resistance Point 163.25
1st Resistance Point 159.09
Last Price 154.94
1st Support Level 152.50
2nd Support Level 150.07
3rd Support Level 145.91

See More

52-Week High 160.81
Last Price 154.94
Fibonacci 61.8% 120.20
Fibonacci 50% 107.65
Fibonacci 38.2% 95.11
52-Week Low 54.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.